It is imperative to highlight that in addition to controlling the LDL receptor expression and serum LDL levels, PCSK9 appears to play conflicting roles in atherosclerosis development, inflammation, thrombosis, apoptosis, diabetes, obesity, hypertension, and Alzheimer’s disease (reviewed in [50]). This evidence concerns the gene LDLR and atherosclerosis.